Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司同类业务(deal/order/contract等)的单个规模在逐步增大?需要寻找管理层自己的表述,对比公司自身近期过去,且是已实现、正在发生的模式,而非仅预期。 在记录中,Barak Eilam提到:“In 2023, we saw a 32% increase in the total ACV of CXone competitive displacements. In fact, we delivered a 40% increase year-over-year in cloud enterprise deals, each with an ACV exceeding $1 million.” 这表示竞争性替换的ACV总额增加,以及超过100万美元ACV的云企业交易数量增加40%。但这是关于交易数量或总额,而非单个交易的平均规模。需要看是否有关于单个交易规模增大的表述。 再找:“We are leading the cloud migration at the high end of the market, with 26% growth in enterprise cloud customers, building over $1 million in ARR.” 这是客户数量增长。 “In Q4, bookings from new customers adopting CXone as a platform increased to 100%. In these deals, customers selected CXone with three or more applications, displacing at least two incumbent point solutions.” 这表示新客户采用平台(三个以上应用)的比例达到100%,但这是关于范围(scope)而非规模?可能暗示每个新客户购买更多应用,但这是否是“same offering”的规模增大?需要看是否对比过去。 管理层没有明确说“平均交易规模比过去大”或“新客户起点比老客户高”等。他们提到“we signed a seven-digit CXone deal with a very large provider...”,但这是单个例子。 关于AI:“we saw a 375% increase in Enlighten bookings in Q4.” 这是增长,但未提及单个规模。 Beth提到:“we expect that 18% to be steady and really play out pretty uniformly in terms of the quarterly growth year-over-year each and every quarter.” 这是关于增长率的稳定性。 没有找到管理层明确对比公司自身过去交易规模增大的表述。他们提到“40% increase in cloud enterprise deals each with ACV exceeding $1 million”可能意味着更多这样的交易,但未说平均规模增大。也没有说“新客户现在一开始就购买更多”或“合同期限更长”等。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.